ACTIVE LOADED FIXATION DEVICES

• US 20140107699A1
• Filed: 10/11/2013
• Published: 04/17/2014
• Est. Priority Date: 10/11/2012
• Status: Abandoned Application

• Current Assignee: Smith & Nephew Incorporated (Smith & Nephew PLC)
• Original Assignee: Smith & Nephew Incorporated (Smith & Nephew PLC)
• Inventors: Thompson, Andrew Fraser
• Application Number:
  US14/052,143
• Publication Number:
  US 20140107699A1
• Time in Patent Office: Days
• US Class Current: 606/231
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 31/005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: C12N 5/0081 Purging biological preparations of unwanted cells

Abstract

The present disclosure relates to methods for producing, including intra-operatively obtaining, a fixation device, and fixation devices produced thereby, containing an autologous cell concentrate from a physiological solution, wherein the cell concentrate is isolated without the need for centrifugation.

Claims

1. A method for producing a fixation device comprising an autologous cell concentrate from a physiological solution, wherein the method comprises:

i) providing a physiological solution not previously subjected to centrifugation;

ii) subjecting the physiological solution to at least one filter to produce at least a first filter retentate and a first filter permeate solution, the first filter retentate comprising platelets, nucleated cells, or both, per unit volume greater than in the physiological solution, and wherein the first permeate solution comprises plasma and red blood cells;

iii) removing the first filter retentate from the filter to provide an autologous cell concentrate; and

iv) subjecting a fixation device to at least the first autologous cell concentrate.

2. The method of claim 1, wherein the fixation device is prepared intra-operatively.

3. The method of claim 1, wherein the first filter is a nucleated cell filtration device.

4. The method of claim 1, further comprising subjecting the first filter retentate to a second filtration.

5. The method of claim 4, wherein the second filtration utilizes a second filter comprising a hollow fiber filter.

6. The method of claim 5, wherein the first and/or second filters comprise a pore size between about 0.05 μ

m and about 5 μ

m.

7. The method of claim 5, wherein the first and/or second filters comprise a pore size between about 0.2 μ

m and about 0.5 μ

m.

8. The method of claim 1, further comprising combining an additional solution with the physiological solution, wherein the additional solution comprises bone marrow aspirate, blood, or a mixture thereof.

9. The method of claim 1, wherein the nucleated cells are at least one selected from the group consisting of stem cells, connective tissue progenitor cells, osteoprogenitor cells, or chondroprogenitor cells.

10. The method of claim 9, wherein the stem cells are mesenchymal stem cells, hematopoietic stem cells, or both.

11. The method of claim 1, wherein the fixation device is selected from at least one of the group consisting of sutures, tissue anchors, or bone anchors.

12. The method of claim 1, wherein the fixation device is a suture.

13. The method of claim 1, wherein providing the physiological solution comprises aspirating bone marrow from an individual into a first syringe to produce a bone marrow aspirate.

14. The method of claim 13, wherein the first syringe comprises an anti-coagulant, an isotonic solution, or both.

15. The method of claim 2, wherein the filtration and intra-operative loading is carried out in a single step.

16. A fixation device substantially coated with an autologous cell concentrate comprising:

i) a fixation device;

ii) at least one component of the fixation device substantially coated with an autologous cell concentrate, the autologous cell concentrate comprising substantially platelets, nucleated cells, or both, and substantially no plasma or red blood cells, wherein the autologous cell concentrate has been prepared by subjecting a physiological solution to a filter to produce a filter retentate and a permeate solution, the filter retentate comprising platelets, nucleated cells, or both per unit volume greater than in the physiological solution, and wherein the permeate solution comprises plasma and red blood cells.

17. The device of claim 16, wherein the fixation device is prepared intra-operatively.

18. The device of claim 16, wherein the filter is a nucleated cell filtration device.

19. The device of claim 18, wherein the filter comprises a pore size between about 0.05 μ

m and about 5 μ

m.

20. The device of claim 18, wherein the filter comprises a pore size between about 0.2 μ

m and about 0.5 μ

m.

21. The device of claim 16, the autologous cell concentrate further comprising bone marrow aspirate, blood, or a mixture thereof.

22. The device of claim 16, wherein the nucleated cells are at least one selected from the group consisting of stem cells, connective tissue progenitor cells, osteoprogenitor cells, or chondroprogenitor cells.

23. The device of claim 22, wherein the stem cells are mesenchymal stem cells, hematopoietic stem cells, or both.

24. The device of claim 16, wherein the fixation device is at least one selected from the group consisting of sutures, tissue anchors, or bone anchors.

25. The device of claim 16, wherein the fixation device is a suture.

26. The device of claim 16, wherein the at least one component of the fixation device that is coated is at least one strand of the suture.

27. An autologous cell concentrate coated suture comprising:

at least one strand of a suture substantially coated with an autologous cell concentrate comprising platelets, nucleated cells, or both.

28. The coated suture of claim 27, wherein the autologous cell concentrate comprises at least nucleated cells selected from the group consisting of stem cells, connective tissue progenitor cells, osteoprogenitor cells, or chondroprogenitor cells.

29. The coated suture of claim 27, wherein the autologous cell concentrate comprises stem cells.

30. The coated suture of claim 27, wherein the autologous cell concentrate comprises osteoprogenitor cells, chondroprogenitor cells, or both.